Well to lay out what you are inferring, if a DMC member was bias (more interested in competitor) and recommended they halt Dr. Liau's trial prematurely, with, how did Dr. Linda Liau's slide generally put it about immunotherapy (during the DCVax-L trial presentation), people need to look at more than 1 yr survival and instead look at long time survival Hazard Ratio. Huh....I wonder if she gave that hypothetical example for a reason? When was it the halt occurred? Oh yeah, when really only one year data could be available for the 50% -60% of the trial. When did it lift? Oh yeah, when about 80% of the trial population had made it past two years. Hypothetically.
Market Data 
Markets 
AI
